Product Name:

NebuPeptide™ Linaclotide (Peptide Reference)

Catalog Number:

NBS-233770

Description:

NebuPeptide™ Linaclotide (Peptide Reference)(CAT#NBS-233770) is synthesized in accordance with the Linaclotide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Lanreotide reference peptide ranging from milligrams to kilograms.

Peptide Name:

Linaclotide (利那洛肽)

Background:

Linaclotide (trade name Linzess in the US and Mexico, and as Constella elsewhere) is a novel, potent, selective and orally administered, peptide agonist of guanylate cyclase C developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. It has a black box warning regarding the possibility of severe dehydration in US children; gastrointestinal side effects are the most frequent in other cases.

Alias:

MM 416775; MM416775; MD-1100 acetate; MM-416775; Linzess; Linaclotide acetate; Linzess Constela

CAS Number:

851199-59-2

Formula:

C59H79N15O21S6

Molecular Weight:

1526.74

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.